Clinical Trial Update: Safety of Vero Cell - Derived Inactivated Japanese Encephalitis Vaccine (JECEVAX) in Children From 9-24 Months of Age [Phase 2]

View source ↗

Summary

Phase 2 trial update assessing safety of Vero cell-derived inactivated JE vaccine JECEVAX in children aged 9-24 months.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Japanese Encephalitis

Drugs mentioned

• JECEVAX

Snippet

Sponsor: National Institute of Hygiene and Epidemiology, Vietnam | Conditions: Japanese Encephalitis | Phase 2 | Status: COMPLETED